Could Faricimab Data Help Roche Maintain Ophthalmic Market Foothold?

The company published data for the bispecific antibody in wet AMD and DME, with non-inferior efficacy to Eylea and growing support for less frequent administration.

Female eye with long eyelashes close up. Closeup shot of female gray - blue colour eye with day makeup. Beauty female eye with curl long eyelashes
Roche's Genentech published Phase III data for faricimab in wet AMD and DME • Source: Shutterstock

Roche Holding AG’s Genentech is looking to retain its position in the ophthalmology market as one of its leading products faces market erosion due to biosimilar competition while gene therapy competitors potentially gain ground as well. The publication of Phase III data for its bispecific antibody faricimab in wet age-related macular degeneration (AMD) and diabetic macular edema (DME) reinforces the drug’s market potential, particularly the possibility of less-frequent dosing resulting in fewer patients lost to follow-up.

Faricimab, a bispecific antibody targeting vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Ang-2), is under US Food and Drug Administration...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Sensory

Sponsored By

Nancy Tests SPARC-931 Part 8

This is a short description. This is a short description.

Small But Mitey: Tarsus To Amp Up Strong Xdemvy Launch

 

Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.    

Acelyrin Belatedly Drops Izokibep In Its Lead Indications

 

The group has stopped further development of the IL-17A inhibitor in hidradenitis suppurativa and psoriatic arthritis, and intends to pivot to a thyroid eye disease therapy.  

Aldeyra Readies Reproxalap For Dry Eye Refiling After Chamber Study Success

 
• By 

The company said earlier this year that it would resubmit reproxalap for US FDA approval before the end of 2024 once it completed another Phase III trial and is eyeing both acute and chronic use.

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.